Shingles Vaccine & Heart Health: 8-Year Protection
The shingles vaccine dramatically cuts your cardiovascular risk. A new study shows a 23% lower risk of heart problems for those vaccinated against shingles, with protection lasting up to eight years. This research, published in the European Heart Journal, tracked over 1.2 million adults and found the benefits most pronounced in men, younger adults, and those with less healthy lifestyles. The shingles vaccine may reduce heart disease risk by preventing complications. Discover how this preventative cardiology breakthrough could impact your health, especially with shingles prevention forming a crucial health defense, as explored by News Directory 3. What dose the future of this connection hold? discover what’s next in this evolving area.
Shingles Vaccine Linked to Lower Cardiovascular Risk
Updated May 29, 2025
The shingles vaccine may offer an unexpected benefit: reduced risk of cardiovascular events.A study published in the European Heart Journal found that individuals who received the vaccine experienced a 23% decrease in the likelihood of stroke, heart failure, and coronary heart disease.
The research, led by Professor Dong Keon Yon of Kyung Hee University, South Korea, tracked over 1.2 million individuals aged 50 and older. The protective effect of the shingles vaccine, a key tool in shingles prevention, was observed for up to eight years, particularly among men, those under 60, and individuals with less healthy lifestyles.
Yon noted that shingles, characterized by a painful rash, can lead to serious health issues, especially in older adults. He added that prior research indicated approximately 30% of individuals might develop shingles without vaccination. The study aimed to determine if the shingles vaccine, a focus of preventative cardiology, could mitigate the increased risk of heart problems associated with the infection.
The study considered factors such as age, sex, wealth, and lifestyle. The live zoster vaccine, containing a weakened form of the varicella zoster virus, was examined.While many countries are transitioning to non-live, recombinant vaccines, this research provides valuable insights into the potential cardiovascular benefits of shingles vaccination.
The data revealed a 26% lower risk of major cardiovascular events (stroke, heart attack, or heart disease-related death), a 26% lower risk of heart failure, and a 22% lower risk of coronary heart disease among vaccinated individuals. The strongest protection was observed within the first two to three years after vaccination, but the benefits extended for up to eight years.
Our study suggests that the shingles vaccine may help lower the risk of heart disease, even in people without known risk factors. This means that vaccination could offer health benefits beyond preventing shingles.
What’s next
Professor Yon and his team plan to investigate the impact of the recombinant vaccine to determine if it offers similar cardiovascular benefits. Further research is needed to confirm these findings across diverse populations and to establish a direct causal relationship.